Video
Dr. Voss on Phase I/II Trial Data of MEDI0680/Durvalumab Versus Nivolumab in mRCC
Author(s):
In Partnership With:
Martin H. Voss, MD, discusses results of a randomized phase I/II trial looking at the combination of MEDI0680 and durvalumab (Imfinzi) versus nivolumab (Opdivo) in metastatic renal cell carcinoma.
Martin H. Voss, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses results of a randomized phase I/II trial (NCT02118337) looking at the combination of MEDI0680 and durvalumab (Imfinzi) versus nivolumab (Opdivo) in metastatic renal cell carcinoma (mRCC).
For the phase I/II trial, investigators set out to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of MEDI0680 in combination with durvalumab compared with nivolumab monotherapy in immunotherapy-naïve patients with metastatic clear cell renal cell carcinoma.
However, no significant difference in overall response rate, progression-free survival, or overall survival was observed between the 2 arms of this trial, says Voss. Furthermore, no subgroups appeared to derive additional benefit from the combination versus the single-agent, explains Voss.
Results from a safety analysis showed that grade 3/4 treatment-related adverse events (TRAEs) occurred in 26% of patients who received the combination versus 19% who received nivolumab. Furthermore, 12% of patients discontinued treatment as a result of TRAEs compared with 5%, respectively, Voss concludes.
